source
- Agios cuts over 35% of R&D staff as FDA decision on sickle cell drug is delayedAgios announced it will eliminate more than 100 R&D positions, representing over a third of its research staff, after the FDA postponed a decision on its sickle cell disease candidate. The company…
- Sarepta CEO Sees Path to Stronger DMD Trials Amid 2025 Elevidys SetbacksSarepta Therapeutics’ newly appointed chief executive Michael Severino, after a 90‑day assessment period, outlined a plan to restore the company’s leadership in the Duchenne muscular dystrophy mark…